Skip to content

G&A at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$20.84M+10.8%
Royalty Pharma logo
Royalty PharmaRPRX
$159.49M+44.1%
Zymeworks logo
ZymeworksZYME
$15.07M-11.3%
Xencor logo
XencorXNCR
$17.71M+2.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$13.44M-44.8%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's G&A?
XOMA Corporation (XOMA) reported G&A of $11.86M in Q1 2026.
How has XOMA Corporation's G&A changed year-over-year?
XOMA Corporation's G&A increased by 45.6% year-over-year, from $8.15M to $11.86M.
What is the long-term trend for XOMA Corporation's G&A?
Over 4 years (2021 to 2025), XOMA Corporation's G&A has grown at a 15.2% compound annual growth rate (CAGR), from $20.46M to $36.09M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.